Immunoconjugates
US11130822B2 · kind B2 · utility
13Cited by
21References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 3, 2019 |
| Grant date | Sep 28, 2021 |
| Priority date | — |
| Expiry date | Jun 3, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.